CLAIMS

VACCINE COMPOSITION CONTAINING TRANSFORMING GROWTH FACTOR ALPHA (TGFα). IT USE IN MALIGNANT DISEASES THERAPY.

1 – Vaccine composition containing self-TGFα or any derived or its combination with other EGF-R ligands, coupled with any carrier protein genetically or by chemical conjugation that contains an adjuvant, able to produce a specific immune response against the self-TGFα.

2 – Vaccine composition according to claim1 containing recombinant human TGFα.

3 - Vaccine composition according to claim1 wherein the carrier protein used is P64k.

4 - Vaccine composition according to claim1 that contains a recombinant fusion protein between TGFα and P64k cloned in any expression vector system such as: mammalian cells, bacteria or yeast.

5 - Vaccine composition according to claim1 that contains a recombinant fusion protein between TGFα and P64k cloned in a expression vector of bacteria and expressed in E.coli.

6 - Vaccine composition according to claim1 that contains a recombinant fusion protein between hTGFα and P64k cloned in a expression vector of bacteria that presents a genetic sequence coding for six histidines in the N-terminal end of P64k and expressed in E.coli.

7 - Vaccine composition according to claim1 that contains a chemical conjugated between TGFα and P64k.

8 - Vaccine composition according to claim1 that contains TGFα, EGF and P64k coupled by a chemical method.

9 - Vaccine composition according to claim1 that contains TGFα, EGF and P64k in a recombinant fusion protein cloned in a expression vector of bacteria and expressed in E.coli.

10 – Vaccine composition that represents the mix of two vaccine preparations containing the chemical conjugated between P64k and TGFα or EGF respectively in the moment of the injection

11 - Vaccine composition that represents the mix of two vaccine preparations containing fusion proteins between the P64k and TGFα or EGF respectively in the moment of injection.

12 - Vaccine composition according to claim1 wherein the adjuvant is incomplete adjuvant of Freund.

13 - Vaccine composition according to claim1 wherein the adjuvant is $Al(OH)_3$.

14 - Immunization method with a vaccine composition according to claim 1 to 13, able to achieve specific antibodies against hTGFα.

15 - Treatment method according to claim 14, able to generate anti- hTGFα antibodies, capable of avoid the TGFα bind to its receptor in an in vitro experiment.

16 - Treatment method according to claim 14, able to generate anti-hEGF antibodies.

17 - Treatment method according to claim 14, able to generate anti- hTGFα antibodies, able of recognize TGFα in human tumor biopsies.

18 - Method of treatment of malignant diseases, such as epidermoide breast carcinomas, prostate, gastric, ovary epithelial cancer that express TGFα and other ligands of EGF-R, such as EGF, with a vaccine composition according to claims 1 to 13.